Lundbeck held its Annual General Meeting on 21 March 2013 at the company's registered office

H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting on 21 March 2013 the report by the Board of Directors was adopted and the annual report was approved.

The General Meeting approved the remuneration for the Board of Directors for 2013.

The General Meeting approved the dividend of DKK 2.00 per share of DKK 5 nominal value proposed by the Board of Directors.

Håkan Björklund, Christian Dyvig, Thorleif Krarup, Jes Østergaard and Melanie G. Lee were re-elected, while Lars Rasmussen was elected to the Board of Directors. Mats Pettersson did not stand for re-election. Immediately after the general meeting, the Board of Directors elected Håkan Björklund as Chairman and Christian Dyvig as Deputy Chairman of the Board of Directors.

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Thorleif Krarup, Håkan Björklund and Lars Rasmussen were elected as members of the Audit Committee. Håkan Björklund, Christian Dyvig and Lars Rasmussen were elected as members of the Remuneration Committee. Jes Østergaard, Christian Dyvig and Melanie G. Lee were elected as members of the Scientific Committee.

The Board of Directors of H. Lundbeck A/S will hereafter comprise:

•               Håkan Björklund (Chairman)

•               Christian Dyvig (Deputy Chairman)

•               Thorleif Krarup

•               Jes Østergaard

•               Melanie G. Lee

•               Lars Rasmussen

•               Mona Elisabeth Elster (employee representative)

•               Jørn Møller Mayntzhusen (employee representative)

•               Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor.

The proposal of the Board of Directors to give the Board of Directors authorisation to let the company acquire its own shares was adopted.

No other business was transacted at the Annual General Meeting.

The Board of Directors

Financial guidance

The content of this release will have no influence on the Lundbeck Group's financial guidance for 2013, which was provided on 6 February 2013 in connection with the release of the financial results for 2012.

Lundbeck contacts

About Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the entire value chain throughout research, development, production, marketing and sales of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy, Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck’s pipeline consists of several mid- to late- stage development programs.

Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have research centers in Denmark, China and the United States and production facilities in Italy, France, Mexico, China and Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012. For additional information, we encourage you to visit our corporate site www.lundbeck.com.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.